To the Editor The trial by Dr Bove and colleagues1 found that the renal vasodilator fenoldopam did not reverse acute kidney injury (AKI) after cardiac surgery, in contrast to previous trials and meta-analyses. The failure of this selective renal vasodilator to prevent further deterioration of AKI supports current concepts that several pathophysiological mechanisms besides renal hypoperfusion are involved in AKI associated with on-pump cardiac surgery.
Legrand M, Darmon M, Joannidis M. Fenoldopam and Acute Kidney Injury. JAMA. 2015;313(9):970-971. doi:10.1001/jama.2015.410